- Home
- NRT vs TCRX Comparison
NRT vs TCRX Comparison
Compare NRT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRT | TCRX |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 75.1M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRT | TCRX |
|---|---|---|
| Price | $7.79 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 60.2K | ★ 471.7K |
| Earning Date | 05-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.18% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $4.76 | $0.88 |
| 52 Week High | $10.49 | $2.57 |
Technical Indicators
Market Signals| Indicator | NRT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 37.06 |
| Support Level | $7.64 | $0.91 |
| Resistance Level | $8.68 | $1.16 |
| Average True Range (ATR) | 0.37 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 45.16 | 0.62 |
Price Performance
Historical ComparisonAbout NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.